Category: Consumer goods
Quick infos Headquarters: Philadelphia, Pennsylvania, United States Trade prices Volume: Market Cap: 38.19M Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: Next ER: November 9, 2022
Earnings History Date EPS / Forecast Revenue / Forecast February 16, 2023 November 9, 2022 5.93 / 5.36533.9M / 504.9MBeat! August 12, 2022 -0.42 / -0.09-32M / -3MMay 6, 2022 -0.24 / -0.0077-14.3M / 3.1MMarch 30, 2022 -0.19 / -0.0077-6M / 1Mview more
Historical Data Date Price Open High Low Vol Change ER Mar 30, 2022 5.12 5.48 5.48
4.81
1.83M -6.91% Mar 29, 2022 5.50 5.32 5.59
5.26
588.88K 3.77% Mar 28, 2022 5.30 5.30 5.46
5.25
251.10K -0.56% Mar 25, 2022 5.33 5.21 5.35
5.14
372.56K 2.50% Mar 24, 2022 5.20 5.20 5.35
5.16
659.28K 0.19% Mar 23, 2022 5.19 5.09 5.21
5.05
248.89K 2.98% Mar 22, 2022 5.04 5.00 5.05
4.95
259.15K 1.20% Mar 21, 2022 4.98 5.01 5.01
4.94
14.29K -0.4% Mar 18, 2022 5.00 4.98 5.04
4.92
53.84K 0.20% Mar 17, 2022 4.99 4.94 5.00
4.87
97.27K 1.01% view more
News
AIM ImmunoTech GAAP EPS of -$0.13 misses by $0.01 seekingalpha.com Nov 15, 2022 8:39 pm AIM ImmunoTech soars on FDA orphan drug tag for Ampligen to treat Ebola virus disease seekingalpha.com Nov 2, 2022 8:51 pm AIM ImmunoTech says court denies activist request on board nominees seekingalpha.com Oct 31, 2022 9:35 pm AIM ImmunoTech commences phase 2 study of Ampligen for treatment of pancreatic cancer seekingalpha.com Aug 18, 2022 10:02 pm AIM ImmunoTech reports Q2 results seekingalpha.com Aug 15, 2022 8:47 pm AIM ImmunoTech to further study long COVID therapy after early positive data seekingalpha.com Jul 28, 2022 10:08 pm AIM ImmunoTech receives patent coverage in Netherlands for potential COVID-19 treatment seekingalpha.com Jun 13, 2022 10:56 pm AIM working on new drug application for Ampligen mid-stage study to treat long COVID seekingalpha.com May 18, 2022 9:27 pm AIM ImmunoTech gains on data for Ampligen/checkpoint inhibitor combo in cancer seekingalpha.com Apr 21, 2022 9:02 pm AIM ImmunoTech gains on positive data for Ampligen from two cancer trials seekingalpha.com Apr 11, 2022 7:54 pm Seeking Alpha's Catalyst Watch: Healthcare spotlight on AACR, Bed Bath & Beyond earnings and Elon Musk's TED talk seekingalpha.com Apr 9, 2022 3:00 am AIM ImmunoTech GAAP EPS of -$0.04 seekingalpha.com Apr 1, 2022 4:43 am Long COVID, the next frontier for vaccine and drug developers seekingalpha.com Mar 26, 2022 1:36 am AIM Immunotech stock soars 25% as FDA lifts hold, paving way for pancreatic cancer study seekingalpha.com Mar 16, 2022 7:47 pm AIM ImmunoTech's Ampligen helps improve survival of pancreatic cancer patients in study seekingalpha.com Mar 9, 2022 6:46 pm AIM Immunotech announces sale of New Brunswick, New Jersey facility seekingalpha.com Mar 7, 2022 9:51 pm AIM ImmunoTech appoints Dickey IV as CFO seekingalpha.com Mar 3, 2022 9:55 pm AIM ImmunoTech reports positive data from phase1/2 trial in ovarian cancer seekingalpha.com Jan 25, 2022 4:53 am AIM ImmunoTech EPS in-line seekingalpha.com Nov 16, 2021 8:11 pm AIM ImmunoTech submits IND and Fast Track application for Ampligen in pancreatic cancer seekingalpha.com Oct 19, 2021 7:41 pm AIM Dividends Ex-Dividend Amount Announced Date Record Date Payment Date Jun 14, 2017 0.8 Dec 28, 2018 Mar 15, 2017 0.8 Mar 31, 2017 Sep 14, 2016 0.8 Sep 30, 2016 Jun 14, 2016 0.8 Jun 30, 2016 Mar 15, 2016 0.76 Mar 31, 2016 view more
Talk about AIM ImmunoTech Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.
